![conference banner](/images/conference-banner.jpeg)
摘要
目前已批准了五种程序性死亡-1 /程序性死亡配体1(PD-L1)抑制剂用于治疗膀胱和上尿路的局部晚期或转移性尿路上皮癌。 FDA和EMA限制不适合铂类患者使用Atezolizumab和Pembrolizumab一线治疗的限制后,现在需要进行免疫组织化学PD-L1检测。 关于抗体,测试平台和评分算法的一些新出现的问题引起了人们对这些试验之间可比性和互换性的担忧。 在这篇综述中,我们集中于尿路上皮癌PD-L1检测所用算法和测定法的互换性,尿路上皮癌PD-L1检测的预测可靠性以及其他新的和即将出现的生物标记物的潜力。
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
Current Drug Targets
Title:PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives
Volume: 22 Issue: 2
关键词: PD-L1,免疫组化,尿路上皮癌,生物标志物,互换性,免疫疗法。
摘要: Five programmed death-1/programmed death-ligand 1 (PD-L1) inhibitors are currently approved for the treatment of locally advanced or metastatic urothelial carcinoma of the bladder and the upper urinary tract. Following the FDA and EMA restrictions of first-line treatment with Atezolizumab and Pembrolizumab in platinum-ineligible patients, immunohistochemical PD-L1 testing is now required. Several emerging issues on antibodies, test platforms and scoring algorithms have raised concerns about the comparability and interchangeability between these assays. In this review, we have focused on the interchangeability of the used algorithms and assays for PD-L1 testing in urothelial carcinoma, on the predictive reliability of PD-L1 testing in urothelial carcinoma and the potential of other new and upcoming biomarkers.
Export Options
About this article
Cite this article as:
PD-L1 Testing for Urothelial Carcinoma: Interchangeability, Reliability and Future Perspectives, Current Drug Targets 2021; 22 (2) . https://dx.doi.org/10.2174/1389450121666200510015216
DOI https://dx.doi.org/10.2174/1389450121666200510015216 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy
Current Drug Metabolism The Complexity of Aging: Cancer Risk Among Elderly People and Infectious Risk Among Those with Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review on Natural Sources Derived Protein Nanoparticles as Anticancer Agents
Current Topics in Medicinal Chemistry Pentacyclic Triterpenoids and Their Saponins with Apoptosis-Inducing Activity
Current Topics in Medicinal Chemistry Costimulation, Coinhibition and Cancer
Current Cancer Drug Targets Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease
Current Alzheimer Research Evaluation of Tricine and EDDA as Co-ligands for <sup>99m</sup>Tc-Labeled HYNIC-MSH Analogs for Melanoma Imaging
Anti-Cancer Agents in Medicinal Chemistry A Detailed Review of Molecular Pathways and Mechanisms Responsible for the Development and Aggravation of Neuropathy and Nephropathy in Diabetes
Current Molecular Pharmacology The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Emerging Role of ImmunoPET in Receptor Targeted Cancer Therapy
Current Drug Delivery Assessment of Diagnostic Performance of Risk Factors Affecting Extraprostatic Extension: Role of Zonal Level of Prostate Cancer
Current Medical Imaging Diselenides and Selenocyanates as Versatile Precursors for the Synthesis of Pharmaceutically Relevant Compounds
Current Organic Synthesis Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Time Dependent Distribution of MicroRNA 144 after Intravenous Delivery
MicroRNA Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets